238
Participants
Start Date
September 17, 2013
Primary Completion Date
August 30, 2015
Study Completion Date
January 22, 2022
Vandetanib (SAR390530)
"Pharmaceutical form: tablet~Route of administration: oral"
Placebo
"Pharmaceutical form: tablet~Route of administration: oral"
Research Site, New York
Research Site, Philadelphia
Research Site, Ann Arbor
Washington University, St Louis
Research Site, Little Rock
Research Site, Torrance
Research Site, Portland
Research Site, Lexington
Research Site, Boston
Research Site, Omaha
Research Site, Porto Alegre
Research Site, Ribeirão Preto
Research Site, Rio de Janeiro
Research Site, São José do Rio Preto
Research Site, São Paulo
Research Site, Beijing
Research Site, Changchun
Research Site, Chengdu
Research Site, Huangzhou
Research Site, Shanghai
Research Site, Tianjin
Research Site, Wuhan
Research Site, Olomouc
Research Site, Prague
Research Site, Odense
Research Site, Angers
Research Site, Bordeaux
Research Site, Caen
Research Site, Paris
Research Site, Villejuif
Research Site, Catania
Research Site, Milan
Research Site, Napoli
Research Site, Pisa
Research Site, Roma
Research Site, Siena
Research Site, Bunkyō City
Research Site, Fukuoka
Research Site, Fukushima
Research Site, Kashiwa-shi
Research Site, Kobe
Research Site, Kōtoku
Research Site, Matsumoto-shi
Research Site, Nagasaki
Research Site, Nagoya
Research Site, Niigata
Research Site, Osaka
Research Site, Shinjuku-ku
Research Site, Yokohama
Research Site, Gliwice
Research Site, Kielce
Research Site, Warsaw
Research Site, Zgierz
Research Site, Barnaul
Research Site, Obninsk
Research Site, Barcelona
Research Site, Girona
Research Site, Hospitalet de Llobregat(Barcel
Research Site, Madrid
Research Site, Lund
Research Site, Stockholm
Genzyme, a Sanofi Company
INDUSTRY